BD Biosciences announced last week the availability of the BD FACSArray bioanalyzer, a platform for rapid high-content analysis of proteins in cell biology, immunology, and proteomics. The platform is capable of multiplexed bead-based and cellular assays, BD said.
BD Biosciences Clontech also announced last week the availability of the BD Living Colors AcGFP1, a fluorescent protein derived from the jellyfish Aequorea coerulescens. The company said that AcGFP is an alternative to enhanced GFP, which the company discontinued due to expiration of a product license. The product announcement comes on the heels of the company’s introduction of its dsRed-monomer (see Inside Bioassays, 2/1/2005). BD said that both new fluorescent proteins are ideal for multicolor applications in fluorescence microscopy and flow cytometry.
NanoMarkets has released a new report entitled “The Impact of Nanotechnology in Drug Discovery: Global Developments, Market Analysis, and Future Prospects.”
The 218-page report analyzes drivers, restraints, challenges, regulatory issues, and government funding policies that impact nano-scale drug discovery, and contains profiles of 30 companies active in this space, NanoMarkets said.
The report predicts that by 2009, 19 percent of nano-enabled drug discovery revenues will come from control and analysis of cells; 13 percent from DNA/RNA sizing, electrophoresis, and quantitation; 11 percent from genotyping; and 10 percent from high-throughput screening.
More information on the report can be found at http://www.nanomarkets.net/.